Literature DB >> 22105597

Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?

G Barosi, A Tefferi, T Barbui.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22105597     DOI： 10.1038/leu.2011.337

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

Authors:  Giovanni Barosi; Ruben Mesa; Guido Finazzi; Claire Harrison; Jean-Jacques Kiladjian; Eva Lengfelder; Mary F McMullin; Francesco Passamonti; Alessandro M Vannucchi; Carlos Besses; Heinz Gisslinger; Jan Samuelsson; Srdan Verstovsek; Ronald Hoffman; Animesh Pardanani; Francisco Cervantes; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

2.  How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Authors:  G Barosi; R P Gale
Journal:  Leukemia       Date:  2016-04-29       Impact factor: 11.528

3.  Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Authors:  Luigi Gugliotta; Carlos Besses; Martin Griesshammer; Claire Harrison; Jean-Jacques Kiladjian; Ruth Coll; Jonathan Smith; Brihad Abhyankar; Gunnar Birgegård
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.